The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Open accessAbstract
BACKGROUND: Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a challenge. METHODS: We performed exome sequencing of samples obtained from 151 patients with myeloproliferative neoplasms. The mutation status of the gene encoding calreticulin (CALR) was assessed in an additional 1345 hematologic cancers, 1517 other cancers, and 550 controls. We established phylogenetic trees using hematopoietic colonies. We assessed calreticulin subcellular localization using immunofluorescence and flow cytometry. RESULTS: Exome sequencing identified 1498 mutations in 151 patients, with medians of 6.5, 6.5, and 13.0 mutations per patient in samples of polycythemia vera, essential thrombocythemia, and myelofibrosis, respectively. Somatic CALR mutations were found in 70 to 84% of samples of myeloproliferative neoplasms with nonmutated JAK2, in 8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and in none of the other cancers. A total of 148 CALR mutations were identified with 19 distinct variants. Mutations were located in exon 9 and generated a +1 base-pair frameshift, which would result in a mutant protein with a novel C-terminal. Mutant calreticulin was observed in the endoplasmic reticulum without increased cell-surface or Golgi accumulation. Patients with myeloproliferative neoplasms carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2. Mutation of CALR was detected in hematopoietic stem and progenitor cells. Clonal analyses showed CALR mutations in the earliest phylogenetic node, a finding consistent with its role as an initiating mutation in some patients. CONCLUSIONS: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2. (Funded by the Kay Kendall Leukaemia Fund and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“But many of the most commonly seen mutations in CHIP are also recurrent drivers of AML 64, myelodysplastic syndrome (MDS) 65–67, myeloproliferative neoplasms 68, and certain lymphomas 69,70.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [68]
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062
Self-citationLevine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationClinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Chao MP, 2010, Sci Transl Med, 2, 63ra94
Cited by
Sorted by citations
Items 101–200 of 1,002
Rondelli, D., Goldberg, J. D., Isola, L. M., Price, L. S., Shore, T. B., Boyer, M. J., Bacigalupo, A. P., Rambaldi, A., Scarano, M., Klisovic, R. B., et al. (2014) · Blood · doi:10.1182/blood-2014-04-572545 · Cited by 149
Self-citationTargeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Wen, Q. J., Yang, Q., Goldenson, B., Malinge, S., Lasho, T. L., Schneider, R. K., Breyfogle, L. J., Schultz, R. F., Gilles, L., Koppikar, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3995 · Cited by 157
Harrison, C. N., Koschmieder, S., Foltz, L. M., Guglielmelli, P., Flindt, T., Koehler, M., Mathias, J., Komatsu, N., Boothroyd, R. N., Spierer, A., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3082-y · Cited by 149
Self-citationWiersma, V. R., Michalak, M., Abdullah, T. M., Bremer, E., & Eggleton, P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00007 · Cited by 147
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Gerds, A. T., Gotlib, J. R., Ali, H., Bose, P., Dunbar, A. J., Elshoury, A., George, T. I., Gundabolu, K., Hexner, E. O., Hobbs, G. S., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0046 · Cited by 139
Engaging chromatin: PRC2 structure meets function
Chammas, P., Mocavini, I., & Croce, L. D. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0615-2 · Cited by 149
Inflammation and myeloproliferative neoplasms
Lussana, F., & Rambaldi, A. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.010 · Cited by 136
The role of ASXL1 in hematopoiesis and myeloid malignancies
Asada, S., Fujino, T., Goyama, S., & Kitamura, T. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03084-7 · Cited by 142
Nangalia, J., Nice, F. L., Wedge, D. C., Godfrey, A. L., Grinfeld, J., Thakker, C. E., Massie, C. E., Baxter, E. J., Sewell, D., Silber, Y., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.129510 · Cited by 139
Self-citationGuglielmelli, P., Biamonte, F., Rotunno, G., Artusi, V., Artuso, L., Bernardis, I., Tenedini, E., Pieri, L., Paoli, C., Mannarelli, C., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536557 · Cited by 135
Self-citationClonal hematopoiesis: Mutation-specific adaptation to environmental change
Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129
Hernández–Gea, V., Gottardi, A. D., Leebeek, F. W. G., Rautou, P., Salem, R., & García‐Pagán, J. C. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.015 · Cited by 128
Van Hout, C. V., Tachmazidou, I., Backman, J. D., Hoffman, J. X., Ye, B., Pandey, A. K., Gonzaga-Jauregui, C., Khalid, S., Liu, D., Banerjee, N., et al. (2019) · doi:10.1101/572347 · Cited by 110
Barbui, T., Thiele, J., Gisslinger, H., Finazzi, G., Vannucchi, A. M., & Tefferi, A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.06.001 · Cited by 127
Self-citationTefferi, A., Nicolosi, M., Mudireddy, M., Szuber, N., Finke, C. M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., Gangat, N., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24978 · Cited by 127
Self-citationProteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Barbui, T., Thiele, J., Vannucchi, A. M., & Tefferi, A. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.64 · Cited by 128
Self-citationNorfo, R., Zini, R., Pennucci, V., Bianchi, E., Salati, S., Guglielmelli, P., Bogani, C., Fanelli, T., Mannarelli, C., Rosti, V., et al. (2014) · Blood · doi:10.1182/blood-2013-12-544197 · Cited by 128
Self-citationWang, S. A., Tam, W., Tsai, A. G., Arber, D. A., Hasserjian, R. P., Geyer, J. T., George, T. I., Czuchlewski, D. R., Foucar, K. K., Rogers, H. J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.75 · Cited by 126
Mpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 130
Pathogenesis of myeloproliferative neoplasms
Skoda, R. C., Duek, A., & Grisouard, J. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.06.007 · Cited by 135
Shimizu, T., Kubovčáková, L., Nienhold, R., Zmajkovic, J., Meyer, S. C., Hao-Shen, H., Geier, F. M., Dirnhofer, S., Guglielmelli, P., Vannucchi, A. M., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151136 · Cited by 132
Self-citationKDEL Receptors Are Differentially Regulated to Maintain the ER Proteome under Calcium Deficiency
Trychta, K. A., Bäck, S., Henderson, M. J., & Harvey, B. K. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.055 · Cited by 130
Stivala, S., Codilupi, T., Brkić, Š., Baerenwaldt, A., Ghosh, N., Hao-Shen, H., Dirnhofer, S., Dettmer, M. S., Simillion, C., Kaufmann, B. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci98785 · Cited by 127
Functional Roles of Calreticulin in Cancer Biology
Lu, Y.-C., Weng, W., & Lee, H. (2015) · BioMed Research International · doi:10.1155/2015/526524 · Cited by 122
Immunosuppression by Mutated Calreticulin Released from Malignant Cells
Liu, P., Zhao, L., Loos, F., Marty, C., Xie, W., Martins, I., Lachkar, S., Qu, B., Waeckel-Énée, E., Plo, I., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.004 · Cited by 122
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
Hermouet, S., Bigot‐Corbel, E., & Gardie, B. (2015) · Mediators of Inflammation · doi:10.1155/2015/145293 · Cited by 122
Kim, J., Gee, H. Y., & Lee, M. G. (2018) · Journal of Cell Science · doi:10.1242/jcs.213686 · Cited by 131
Molecular pathogenesis of the myeloproliferative neoplasms
Greenfield, G., McMullin, M. F., & Mills, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01116-z · Cited by 128
Calreticulin mutations and long-term survival in essential thrombocythemia
Tefferi, A., Wassie, E. A., Lasho, T. L., Finke, C. M., Belachew, A. A., Ketterling, R. P., Hanson, C. A., Pardanani, A. D., Gangat, N., & Wolanskyj, A. P. (2014) · Leukemia · doi:10.1038/leu.2014.148 · Cited by 116
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115
Systematic discovery of complex insertions and deletions in human cancers
Ye, K., Wang, J., Jayasinghe, R. G., Lameijer, E.-W., McMichael, J. F., Ning, J., McLellan, M. D., Xie, M., Cao, S., Yellapantula, V. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.4002 · Cited by 118
Cabagnols, X., Defour, J., Ugo, V., Ianotto, J., Mossuz, P., Mondet, J., Girodon, F., Alexandre, J. H., Mansier, O., Viallard, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.270 · Cited by 114
Fisher, D. A. C., Malkova, O., Engle, E. K., Miner, C. A., Fulbright, M. C., Behbehani, G. K., Collins, T. B., Bandyopadhyay, S., Zhou, A. W., Nolan, G. P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.377 · Cited by 113
Biological background of the genomic variations of cf-DNA in healthy individuals
Liu, J., Chen, X., Wang, J., Zhou, S., Wang, C. L., Ye, M. Z., Wang, X. Y., Song, Y., Wang, Y., zhang, L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy513 · Cited by 117
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose, P., & Verstovšek, S. (2017) · Blood · doi:10.1182/blood-2017-04-742288 · Cited by 114
Pereira, C. A., Giménez‐Xavier, P., Pros, E., Pajares, M. J., Moro, M., Gómez, A., Navarro, A., Condom, E., Morán, S., Goméz-López, G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946 · Cited by 111
Kröger, N. M., Panagiota, V., Badbaran, A., Zabelina, T., Triviai, I., Cruz, M. M. A., Shahswar, R., Ayuk, F. A., Gehlhaar, M. A., Wolschke, C., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.034 · Cited by 107
Bozkus, C. C., Roudko, V., Finnigan, J. P., Mascarenhas, J. O., Hoffman, R., Iancu‐Rubin, C., & Bhardwaj, N. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1356 · Cited by 107
Lundberg, P., Takizawa, H., Kubovčáková, L., Guo, G., Hao-Shen, H., Dirnhofer, S., Orkin, S. H., Manz, M. G., & Skoda, R. C. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131371 · Cited by 119
Sashida, G., Wang, C., Tomioka, T., Oshima, M., Aoyama, K., Kanai, A., Mochizuki‐Kashio, M., Harada, H., Shimoda, K., & Iwama, A. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151121 · Cited by 110
Hasselbalch, H. C., & Holmström, M. O. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0700-2 · Cited by 106
Chen, E., Schneider, R. K., Breyfogle, L. J., Rosen, E. A., Poveromo, L., Elf, S., Ko, A., Brumme, K. M., Levine, R. L., Ebert, B. L., et al. (2014) · Blood · doi:10.1182/blood-2014-04-567024 · Cited by 115
Li, J., Prins, D., Park, H. J., Grinfeld, J., Arias, C. G., Loughran, S. J., Dovey, O. M., Klampfl, T., Bennett, C., Hamilton, T. L., et al. (2017) · Blood · doi:10.1182/blood-2017-09-806356 · Cited by 103
Self-citationCalreticulin in phagocytosis and cancer: opposite roles in immune response outcomes
Schcolnik‐Cabrera, A., Oldak, B., Juárez, M., Cruz-Rivera, M. Y., Flisser, A., & Mendlovic, F. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01532-0 · Cited by 105
Mead, A. J., Milojković, D., Knapper, S., Garg, M. K., Chacko, J. M., Farquharson, M., Yin, J. L., Ali, S., Clark, R. E., Andrews, C., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13379 · Cited by 103
Self-citationMolecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
Grinfeld, J., Nangalia, J., & Green, A. R. (2016) · Haematologica · doi:10.3324/haematol.2014.113845 · Cited by 108
Self-citationDistinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
Andrikovics, H., Krähling, T., Balassa, K., Halm, G., Bors, A., Koszarska, M., Bátai, Á., Dolgos, J., Csomor, J., Egyed, M., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.107482 · Cited by 101
Fujino, T., Goyama, S., Sugiura, Y., Inoue, D., Asada, S., Yamasaki, S., Matsumoto, A., Yamaguchi, K., Isobe, Y., Tsuchiya, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22053-y · Cited by 109
Mughal, T. I., Cross, N. C. P., Padron, E., Tiu, R. V., Savona, M. R., Malcovati, L., Tibes, R., Komrokji, R. S., Kiladjian, J., Garcia-Manero, G., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.114660 · Cited by 102
Self-citationPresence of calreticulin mutations in JAK2-negative polycythemia vera
Broséus, J., Park, J.-H., Carillo, S., Hermouet, S., & Girodon, F. (2014) · Blood · doi:10.1182/blood-2014-06-583161 · Cited by 98
Han, L., Schubert, C., Köhler, J., Schemionek, M., Isfort, S., Brümmendorf, T. H., Koschmieder, S., & Chatain, N. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0275-0 · Cited by 98
The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms
Bjørn, M. E., & Hasselbalch, H. C. (2015) · Mediators of Inflammation · doi:10.1155/2015/648090 · Cited by 100
Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer, H. L., & Mesa, R. A. (2014) · Blood · doi:10.1182/blood-2014-05-577635 · Cited by 99
Leukemic Transformation in Myeloproliferative Neoplasms
Yogarajah, M., & Tefferi, A. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.05.010 · Cited by 97
Pecquet, C., Chachoua, I., Roy, A., Balligand, T., Vertenoeil, G., Leroy, E., Albu, R.-I., Defour, J., Nivarthi, H., Hug, E., et al. (2019) · Blood · doi:10.1182/blood-2018-09-874578 · Cited by 96
Bernstein, N., Chapman, M. S., Nyamondo, K., Chen, Z., Williams, N., Mitchell, E., Campbell, P. J., Cohen, R. L., & Nangalia, J. (2024) · Nature Genetics · doi:10.1038/s41588-024-01755-1 · Cited by 108
Self-citationA novel mutation in EED associated with overgrowth
Cohen, A. S. A., Tüysüz, B., Shen, Y., Bhalla, S. K., Jones, S. J. M., & Gibson, W. T. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.26 · Cited by 96
Addicted to secrete – novel concepts and targets in cancer therapy
Dejeans, N., Manié, S. N., Hetz, C. A., Bard, F., Hupp, T. R., Agostinis, P., Samali, A., & Chevet, É. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.12.003 · Cited by 103
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy
Holmström, M. O., Martinenaite, E., Ahmad, S. M., Met, Ö., Friese, C., Kjær, L., Riley, C. H., Straten, P. T., Svane, I. M., Hasselbalch, H. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.214 · Cited by 94
Kumar, A., Sharma, P., & Arora, A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13019 · Cited by 93
The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control
Malara, A., Abbonante, V., Buduo, C. A. D., Tozzi, L., Currao, M., & Balduini, A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1813-y · Cited by 92
Mutant calreticulin in myeloproliferative neoplasms
How, J., Hobbs, G. S., & Mullally, A. (2019) · Blood · doi:10.1182/blood.2019000622 · Cited by 92
Kim, S. Y., Im, K., Park, S. N., Kwon, J., Kim, J., & Lee, D. S. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpuaac16liwzmm · Cited by 92
Leroy, E., & Constantinescu, S. N. (2017) · Leukemia · doi:10.1038/leu.2017.43 · Cited by 92
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN
Elf, S., Abdelfattah, N. S., Baral, A. J., Beeson, D., Rivera, J. F., Ko, A., Florescu, N., Birrane, G., Chen, E., & Mullally, A. (2017) · Blood · doi:10.1182/blood-2017-08-800896 · Cited by 90
Sangkhae, V., Etheridge, S. L., Kaushansky, K., & Hitchcock, I. S. (2014) · Blood · doi:10.1182/blood-2014-07-587238 · Cited by 90
Borowczyk, M., Wojtaszewska, M. L., Lewandowski, K., Gil, L., Lewandowska, M., Lehmann-Kopydłowska, A., Kroll‐Balcerzak, R., Balcerzak, A., Iwoła, M., Michalak, M., et al. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.006 · Cited by 93
Spivak, J. L. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0529-x · Cited by 89
Guglielmelli, P., Rotunno, G., Fanelli, T., Pacilli, A., Brogi, G., Calabresi, L., Pancrazzi, A., Vannucchi, A. M., & (AGIMM), O. B. O. T. A. I. P. L. R. S. C. G. I. M. M. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.90 · Cited by 88
Self-citationMyelofibrosis biology and contemporary management
Gangat, N., & Tefferi, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16576 · Cited by 94
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
Santos, F. P. D. S., Getta, B. M., Masárová, L., Famulare, C. A., Schulman, J., Datoguia, T. S., Puga, R., Paiva, R. D. M. A., Arcila, M. E., Hamerschlak, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0603-9 · Cited by 90
Shallis, R. M., Wang, R., Davidoff, A. J., Ma, X., Podoltsev, N. A., & Zeidan, A. M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100706 · Cited by 91
Xiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症：英文版 · doi:10.1002/cac2.12579 · Cited by 87
Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis
Turón, F., Cervantes, F., Colomer, D., Baiges, A., Hernández–Gea, V., & García‐Pagán, J. C. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.032 · Cited by 86
on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators, Vannucchi, A. M., Rotunno, G., Bartalucci, N., Raugei, G., Carrai, V., Balliu, M., Mannarelli, C., Pacilli, A., Calabresi, L., et al. (2014) · Leukemia · doi:10.1038/leu.2014.100 · Cited by 86
Self-citationThe evolving genomic landscape of myeloproliferative neoplasms
Nangalia, J., & Green, T. R. (2014) · Hematology · doi:10.1182/asheducation-2014.1.287 · Cited by 87
Self-citationBarbui, T., Thiele, J., Carobbio, A., Guglielmelli, P., Rambaldi, A., Vannucchi, A. M., & Tefferi, A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23694 · Cited by 84
Self-citationVarghese, L. N., Defour, J., Pecquet, C., & Constantinescu, S. N. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00059 · Cited by 84
How I treat essential thrombocythemia
Rumi, E., & Cazzola, M. (2016) · Blood · doi:10.1182/blood-2016-05-643346 · Cited by 83
Molecular diagnostics of myeloproliferative neoplasms
Langabeer, S. E., Andrikovics, H., Asp, J., Bellosillo, B., Carillo, S., Haslam, K., Kjær, L., Lippert, É., Mansier, O., Leibundgut, E. O., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12578 · Cited by 84
Finazzi, G., Carobbio, A., Guglielmelli, P., Cavalloni, C., Salmoiraghi, S., Vannucchi, A. M., Cazzola, M., Passamonti, F., Rambaldi, A., & Barbui, T. (2014) · Blood · doi:10.1182/blood-2014-08-596676 · Cited by 82
Self-citationArshad, N., & Cresswell, P. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002836 · Cited by 82
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
Self-citationPatnaik, M. M., & Tefferi, A. (2017) · American Journal of Hematology · doi:10.1002/ajh.24637 · Cited by 81
Nieborowska-Skorska, M., Maifrede, S., Dasgupta, Y., Sullivan, K., Flis, S., Le, B. V., Solecka, M., Belyaeva, E. A., Kubovčáková, L., Nawrocki, M., et al. (2017) · Blood · doi:10.1182/blood-2017-05-784942 · Cited by 81
Molecular insights into regulation of JAK2 in myeloproliferative neoplasms
Silvennoinen, O., & Hubbard, S. R. (2015) · Blood · doi:10.1182/blood-2015-01-621110 · Cited by 81
Greenfield, G., McPherson, S., Mills, K., & McMullin, M. F. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1729-7 · Cited by 83
Ianotto, J., Curto‐García, N., Lauermannová, M., Radia, D. H., Kiladjian, J., & Harrison, C. N. (2019) · Haematologica · doi:10.3324/haematol.2018.200832 · Cited by 80
Self-citationKameda, T., Shide, K., Yamaji, T., Kamiunten, A., Sekine, M., Taniguchi, Y., Hidaka, T., Kubuki, Y., Shimoda, H. K., Marutsuka, K., et al. (2014) · Blood · doi:10.1182/blood-2014-04-555508 · Cited by 87
Thrombopoietin receptor is required for the oncogenic function of CALR mutants
Nivarthi, H., Chen, D., Cleary, C. M., Kubešová, B., Jäger, R., Bogner, E., Marty, C., Pecquet, C., Vainchenker, W., Constantinescu, S. N., et al. (2016) · Leukemia · doi:10.1038/leu.2016.32 · Cited by 80
Delic, S., Rose, D., Kern, W., Nadarajah, N., Haferlach, C., Haferlach, T., & Meggendorfer, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14269 · Cited by 79
JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
McKenney, A. S., Lau, A. N., Somasundara, A. V. H., Spitzer, B. G., Intlekofer, A. M., Ahn, J., SHANK, K. R., Rapaport, F. T., Patel, M. A., Papalexi, E., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94516 · Cited by 81
The role of extracellular matrix stiffness in megakaryocyte and platelet development and function
Leiva, O., Léon, C., Ng, S. K., Mangin, P., Gachet, C., & Ravid, K. (2017) · American Journal of Hematology · doi:10.1002/ajh.25008 · Cited by 81
Myelofibrosis in 2019: moving beyond JAK2 inhibition
Schieber, M., Crispino, J. D., & Stein, B. L. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0236-2 · Cited by 79
Maze, D. C., Kazi, S., Gupta, V. K., Malinowski, A. K., Fazelzad, R., Shah, P. S., & Shehata, N. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12666 · Cited by 77
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
Yi, C. A., Tam, C. S. L., & Verstovšek, S. (2015) · Future Oncology · doi:10.2217/fon.14.272 · Cited by 79
Patnaik, M. M., Lasho, T. L., Finke, C. M., Hanson, C. A., King, R. L., Ketterling, R. P., Gangat, N., & Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24332 · Cited by 77
Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
Cassinat, B., Verger, E., & Kiladjian, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1401255 · Cited by 76
Shide, K., Kameda, T., Yamaji, T., Sekine, M., Inada, N., Kamiunten, A., Akizuki, K., Nakamura, K., Hidaka, T., Kubuki, Y., et al. (2016) · Leukemia · doi:10.1038/leu.2016.308 · Cited by 87
Metadata
- Authors
- Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., Aziz, A., Godfrey, A. L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A. V., Guglielmelli, P., Tarpey, P., Harding, H. P., Fitzpatrick, J. D., Goudie, C. T., Ortmann, C. A., Loughran, S. J., Raine, K., Jones, D. R., Butler, A. P., Teague, J. W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.-Q., Greaves, M., Bowen, D., Huntly, B. J. P., Harrison, C. N., Cross, N. C. P., Ron, D., Vannucchi, A. M., Papaemmanuil, E., Campbell, P. J., & Green, A. R.
- ORCID
- Nangalia, J.
- Massie, C.E.
- Baxter, E.J.
- Nice, F.L.
- Gundem, G.
- Wedge, D.C.
- Avezov, E.
- Kollmann, K.
- Kent, D.G.
- Godfrey, A.L.
- Hinton, J.
- Martincorena, I.
- Jones, A.V.
- Guglielmelli, P.
- Tarpey, P.
- Harding, H.P.
- Fitzpatrick, J.D.
- Loughran, S.J.
- Raine, K.
- Jones, D.R.
- Teague, J.W.
- McLaren, S.
- Hill, K.
- Orchard, K.
- Du, M.-Q.
- Greaves, M.
- Bowen, D.
- Huntly, B.J.P.
- Harrison, C.N.
- Cross, N.C.P.
- Ron, D.
- Vannucchi, A.M.
- Papaemmanuil, E.
- Campbell, P.J.
- Green, A.R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2391-2405
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3966280
- OpenAlex
- W2138709799
- Cited by
- 1,756
- References
- 40
- Citations by year
- 2026: 64 · 2025: 59 · 2024: 72 · 2023: 90 · 2022: 112 · 2021: 133 · 2020: 125 · 2019: 124 · 2018: 130 · 2017: 181 · 2016: 208 · 2015: 239 · 2014: 208 · 2013: 7
- FWCI
- 108.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- University of Salford Institutional Repository (University of Salford) (submittedVersion, cc-by)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Leukemia and Lymphoma Research
- University of Salford Manchester
- Wellcome Trust (079249, 100140, 093867, 084812)
- University Hospital Southampton NHS Foundation Trust
- Cancer Research UK (12526, 12765, 15488)
- National Institute for Health and Care Research (NF-SI-0512-10079)
- Kay Kendall Leukaemia Fund
- University of Southampton
- KU Leuven
- Università degli Studi di Firenze
- Associazione Italiana per la Ricerca sul Cancro
- Vlaamse regering
- Canadian Institutes of Health Research
- Medical Research Council
- Cambridge Institute for Medical Research, University of Cambridge
- NIHR Cambridge Biomedical Research Centre
- Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, myelofibrosis, myelodysplastic syndrome, endoplasmic reticulum chaperone, clonal evolution, hematopoietic stem and progenitor cells, somatic mutations
- MeSH terms
- Amino Acid Sequence, Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Molecular Sequence Data, Mutation, Myelodysplastic Syndromes, Neoplasms, Thrombocythemia, Essential, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
